Vyome Holdings (HIND) AI Stock Analysis

• Market Cap: $18.23M
• Dividend Yield: N/A
• Average Volume (3M): 51.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: -48.74%
• EPS Growth: 89.18%
• Country: US
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.12
• Shares Outstanding: 5,644,494
• 10 Day Avg. Volume: 25,885
• 30 Day Avg. Volume: 51,532
• PEG Ratio: 0.01
• Price to Book (P/B): -36.35
• Price to Sales (P/S): 1.15
• P/FCF Ratio: -2.08
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 2.39
• Enterprise Value/Gross Profit: 3.82
• Enterprise Value/Ebitda: -0.73
• 1Y Price Target: $15.00
• Price Target Upside: 176.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.45
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $3.50 ▼(-35.42% Downside)

The score is held down primarily by weak financial performance (shrinking revenue, deep losses, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events add some upside optionality, but valuation is difficult to justify with a negative P/E and no dividend support.

Positive Factors

Revenue Growth

Consistent revenue growth indicates improved market penetration and product acceptance, which can enhance long-term financial stability.

Cost Reduction

Significant cost reductions enhance profitability and operational efficiency, providing a stronger foundation for future growth.

Regulatory Approval

Health Canada's approval of Lap-Band 2.0 FLEX expands market opportunities, potentially increasing revenue streams and competitive positioning.

Negative Factors

Financial Distress

Negative equity and financial distress indicate potential solvency issues, threatening long-term viability and financial flexibility.

Cash Flow Challenges

Persistent negative cash flow suggests ongoing operational challenges, limiting the company's ability to invest in growth and innovation.

Competitive Pressure

Intense competition from GLP-1 pharmaceuticals could erode market share and hinder revenue growth, impacting long-term competitiveness.

Vyome Holdings Business Overview & Revenue Model

Company Description

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.

How the Company Makes Money

ReShape Lifesciences generates revenue through the sale of its medical device products, primarily the Lap-Band System, to healthcare providers and medical facilities. The company also offers related accessories and support services, which contribute to its revenue streams. Additionally, ReShape may engage in partnerships with healthcare organizations and leverage its intellectual property to enhance its market presence and financial performance. The company's earnings are influenced by factors such as market demand for obesity treatments, competitive positioning, and regulatory approvals.

Vyome Holdings Financial Statement Overview

Summary

ReShape Lifesciences is facing significant financial challenges. Persistent losses, negative equity, and negative cash flows highlight severe operational and financial distress. The company needs substantial improvement in revenue generation, cost management, and financial stability to ensure long-term viability.

Income Statement

ReShape Lifesciences has faced declining revenue, with a 7.76% decrease from 2022 to 2023 and a further 7.75% drop from 2023 to 2024. The company has consistently reported negative EBIT and net income, indicating profitability challenges. Gross profit margin has remained relatively stable but at low levels. Overall, the income statement reflects ongoing financial difficulties and negative growth trends.

Balance Sheet

The balance sheet reveals significant financial distress. The company has a negative stockholders' equity in 2024, highlighting potential solvency issues. The debt-to-equity ratio is not calculable due to negative equity, and the equity ratio shows a negative value, further indicating financial instability. Liabilities exceed assets, showcasing a precarious financial position.

Cash Flow

ReShape Lifesciences has consistently reported negative free cash flow, with no significant improvement over the years. The operating cash flow to net income ratio reflects ongoing operational challenges. Cash flows from operations are negative, and financing activities have been the primary source of cash, which may not be sustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.19M	8.01M	8.68M	11.24M	13.60M	11.30M
Gross Profit	2.62M	5.06M	5.55M	6.80M	8.35M	6.26M
EBITDA	-13.66M	-6.65M	-11.18M	-44.33M	-60.62M	-18.09M
Net Income	-11.51M	-7.13M	-11.39M	-46.21M	-63.15M	-21.63M
Balance Sheet
Total Assets	7.05M	4.79M	10.73M	11.27M	52.53M	39.71M
Cash, Cash Equivalents and Short-Term Investments	5.71M	693.00K	4.56M	3.96M	22.77M	3.01M
Total Debt	38.61K	967.00K	262.00K	171.00K	279.00K	13.25M
Total Liabilities	3.13M	5.05M	4.06M	7.60M	8.20M	25.23M
Stockholders Equity	2.53M	-253.00K	6.66M	3.66M	44.33M	14.49M
Cash Flow
Free Cash Flow	-2.96M	-4.43M	-17.00M	-22.03M	-15.73M	-8.94M
Operating Cash Flow	-2.96M	-4.43M	-16.96M	-21.90M	-15.38M	-8.55M
Investing Cash Flow	0.00	0.00	-10.00K	-92.00K	1.85M	-2.39M
Financing Cash Flow	8.54M	677.00K	17.57M	3.13M	33.30M	11.07M

Vyome Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIND, the sentiment is Negative. The current price of 5.42 is above the 20-day moving average (MA) of 3.57, above the 50-day MA of 4.56, and below the 200-day MA of 13.88, indicating a bearish trend. The MACD of -0.40 indicates Negative momentum. The RSI at 31.25 is Neutral, neither overbought nor oversold. The STOCH value of 16.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIND.

Vyome Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HSCS	46 Neutral	$10.07M	-0.44	-220.42%	―	-41.03%	35.71%
HIND	44 Neutral	$18.23M	-0.02	-565.18%	―	-48.74%	89.18%
HSDT	43 Neutral	$132.58M	>-0.01	―	―	87.45%	72.30%
SINT	40 Underperform	$14.75M	-0.55	-204.04%	―	-60.89%	94.49%
VERO	40 Underperform	$2.83M	-0.03	-854.61%	―	-12.39%	44.61%
MOVE	40 Underperform	$6.06M	-0.31	-398.78%	―	-44.57%	55.97%

Vyome Holdings Corporate Events

Vyome’s LiveChain Signs LOI for Humanyze Note Acquisition

On December 17, 2025, Vyome Holdings, Inc., through its indirect subsidiary LiveChain, Inc. (LICH), entered into a binding letter of intent with Remus Capital Series B II, L.P. to acquire a senior secured convertible note issued by Sociometric Solutions, Inc., d/b/a Humanyze, in exchange for issuing Remus a 25% fully diluted equity stake in LICH immediately prior to closing, with an additional 10% of LICH’s equity reserved for key and future employees, leaving current shareholders with an expected 65% post-closing stake. The transaction, treated as a related party deal and approved by both the company’s Audit Committee and Board after the recusal of Remus-affiliated directors, will be executed through a newly formed LICH subsidiary under a Note Purchase and Exchange Agreement, includes a $20,000 good-faith deposit to Humanyze, grants Remus the right to appoint one LICH director, and is structured to be completed within roughly 75 days of the LOI execution, potentially reshaping LICH’s capital structure and governance while ensuring Humanyze remains active to service select obligations.

The most recent analyst rating on (HIND) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page.

Vyome Holdings Elects Directors at Annual Meeting

On October 28, 2025, Vyome Holdings, Inc. held its 2025 Annual Meeting of Stockholders, where 77.52% of shares were represented. During the meeting, Krishna K. Gupta, Dr. Shiladitya Sengupta, and Mr. Stash Pomichter were elected as Class I directors until 2028. The stockholders approved the 2025 Equity Incentive Plan and ratified Kreit & Chiu CPA LLP as the independent accounting firm for 2025. Additionally, the compensation of named executive officers was approved on a non-binding, advisory basis.

The most recent analyst rating on (HIND) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page.